193 related articles for article (PubMed ID: 33401923)
1. Outcomes of Pediatric Patients With Defibrillators Following Initial Presentation With Sudden Cardiac Arrest.
Robinson JA; LaPage MJ; Atallah J; Webster G; Miyake CY; Ratnasamy C; Ollberding NJ; Mohan S; Von Bergen NH; Johnsrude CL; Garnreiter JM; Spar DS; Czosek RJ
Circ Arrhythm Electrophysiol; 2021 Feb; 14(2):e008517. PubMed ID: 33401923
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
[TBL] [Abstract][Full Text] [Related]
5. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.
DeWitt ES; Triedman JK; Cecchin F; Mah DY; Abrams DJ; Walsh EP; Gauvreau K; Alexander ME
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1057-63. PubMed ID: 25262116
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of implantable cardioverter-defibrillators in adult congenital heart disease patients: indications and outcomes.
Santharam S; Hudsmith L; Thorne S; Clift P; Marshall H; De Bono J
Europace; 2017 Mar; 19(3):407-413. PubMed ID: 27234868
[TBL] [Abstract][Full Text] [Related]
7. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.
Dichtl W; Wolber T; Paoli U; Brüllmann S; Stühlinger M; Berger T; Spuller K; Strasak A; Pachinger O; Haegeli LM; Duru F; Hintringer F
Clin Cardiol; 2011 Jul; 34(7):433-6. PubMed ID: 21678454
[TBL] [Abstract][Full Text] [Related]
8. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Inappropriate Shocks and Other Health Outcomes Between Single- and Dual-Chamber Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter-Defibrillators.
Peterson PN; Greenlee RT; Go AS; Magid DJ; Cassidy-Bushrow A; Garcia-Montilla R; Glenn KA; Gurwitz JH; Hammill SC; Hayes J; Kadish A; Reynolds K; Sharma P; Smith DH; Varosy PD; Vidaillet H; Zeng CX; Normand ST; Masoudi FA
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122811
[TBL] [Abstract][Full Text] [Related]
10. Transvenous and non-transvenous implantable cardioverter-defibrillators in children, adolescents, and adults with congenital heart disease: who is at risk for appropriate and inappropriate shocks?
Krause U; Müller MJ; Wilberg Y; Pietzka M; Backhoff D; Ruschewski W; Paul T
Europace; 2019 Jan; 21(1):106-113. PubMed ID: 30339209
[TBL] [Abstract][Full Text] [Related]
11. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest.
van der Werf C; Lieve KV; Bos JM; Lane CM; Denjoy I; Roses-Noguer F; Aiba T; Wada Y; Ingles J; Leren IS; Rudic B; Schwartz PJ; Maltret A; Sacher F; Skinner JR; Krahn AD; Roston TM; Tfelt-Hansen J; Swan H; Robyns T; Ohno S; Roberts JD; van den Berg MP; Kammeraad JA; Probst V; Kannankeril PJ; Blom NA; Behr ER; Borggrefe M; Haugaa KH; Semsarian C; Horie M; Shimizu W; Till JA; Leenhardt A; Ackerman MJ; Wilde AA
Eur Heart J; 2019 Sep; 40(35):2953-2961. PubMed ID: 31145795
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of implantable cardioverter-defibrillator implantation in secondary prevention of sudden cardiac death.
Boulé S; Sémichon M; Guédon-Moreau L; Drumez É; Kouakam C; Marquié C; Brigadeau F; Kacet S; Potelle C; Escande W; Souissi Z; Lacroix D; Duhamel A; Klug D
Arch Cardiovasc Dis; 2016 Oct; 109(10):517-526. PubMed ID: 27342808
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
Roses-Noguer F; Jarman JW; Clague JR; Till J
Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
[TBL] [Abstract][Full Text] [Related]
15. Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: Improve SCA clinical trial.
Zhang S; Ching CK; Huang D; Liu YB; Rodriguez-Guerrero DA; Hussin A; Kim YH; Chasnoits AR; Cerkvenik J; Lexcen DR; Muckala K; Brown ML; Cheng A; Singh B;
Heart Rhythm; 2020 Mar; 17(3):468-475. PubMed ID: 31561030
[TBL] [Abstract][Full Text] [Related]
16. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
[TBL] [Abstract][Full Text] [Related]
17. Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort.
Heidbuchel H; Willems R; Jordaens L; Olshansky B; Carre F; Lozano IF; Wilhelm M; Müssigbrodt A; Huybrechts W; Morgan J; Anfinsen OG; Prior D; Mont L; Mairesse GH; Boveda S; Duru F; Kautzner J; Viskin S; Geelen P; Cygankiewicz I; Hoffmann E; Vandenberghe K; Cannom D; Lampert R
Eur J Prev Cardiol; 2019 May; 26(7):764-775. PubMed ID: 30813818
[TBL] [Abstract][Full Text] [Related]
18. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of implantable cardioverter-defibrillators in heart transplant recipients: results from a multicenter registry.
Tsai VW; Cooper J; Garan H; Natale A; Ptaszek LM; Ellinor PT; Hickey K; Downey R; Zei P; Hsia H; Wang P; Hunt S; Haddad F; Al-Ahmad A
Circ Heart Fail; 2009 May; 2(3):197-201. PubMed ID: 19808340
[TBL] [Abstract][Full Text] [Related]
20. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
Olde Nordkamp LR; Wilde AA; Tijssen JG; Knops RE; van Dessel PF; de Groot JR
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):91-100. PubMed ID: 23275262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
